No Data
Jiangsu Hengrui Medicine Applies for Drug Marketing Authorization for Insulin Injection
Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for the listing permit of insulin injection pharmaceutical has been accepted.
On January 23, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced it has received the "Acceptance Notice" issued by the National Medical Products Administration. The company's application for a marketing license for the Class 1 therapeutic Biological Product insulin degludec injection has been accepted by the National Medical Products Administration, making it the first domestically developed long-acting insulin analog. Insulin degludec injection is the company's independently developed basic long-acting insulin, featuring a smooth onset of action, prolonged duration of effect, and a low risk of nighttime hypoglycemia.
Jiangsu Hengrui Pharmaceuticals (600276.SH): obtained pharmaceutical registration certificate
On January 20, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceuticals Co., Ltd. received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the compound amino acids (16AA)/glucose (12.6%) electrolyte injection. This product is the first domestically replicated product and is considered to have passed the consistency evaluation of quality and efficacy for generic drugs. The compound amino acids (16AA)/glucose (12.6%) electrolyte injection is a parenteral nutrition preparation that provides parenteral nutrition for adult patients when enteral nutrition is not feasible, inadequate, or contraindicated, supplementing amino acids, electrolytes, and glucose.
The Past Five Years for Jiangsu Hengrui Medicine (SHSE:600276) Investors Has Not Been Profitable
GF SEC: VERTEX JPM meeting update, focusing on the progress in the fields of domestic enterprise pain and kidney disease.
The success of Suzetrigine offers hope for the development of the Nav1.8 target, and based on its inherent mechanism advantages, it is expected to bring a new, safer, and more effective therapy for pain patients.
New stock news | Jiangsu Hengrui Pharmaceuticals, Furuitek, and Jinsheng New Energy's Hong Kong stock IPO application materials have been accepted by the China Securities Regulatory Commission.
Jiangsu Hengrui Pharmaceuticals, Futu Tech, and Jinsheng New Energy have filed for a Hong Kong stock IPO, which has been accepted for record by the China Securities Regulatory Commission.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
